New Leaf Venture Partners
New Leaf Venture Partners is a venture capital firm focused on investments in healthcare technology companies.
Business Model:
Revenue: $18M
Employees: 2-10
Rankings
Industries / Tags:
Detailed New Leaf Venture Partners Information
Geographic Data
Address: Times Square Tower , 7 Times Square
City: New York
State: NY
Zip: 10036
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$400M
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
New Leaf Venture Partners is a venture capital firm that invests primarily in healthcare technology. The company typically focuses on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies. The New Leaf Ventures (NLV) team has been built over a decade, originating within Sprout Group, the venture capital affiliate of Credit Suisse First Boston. Sprout Group was formed in 1969 and has historically been one of the leading venture capital firms in the country. The team started to invest in healthcare technology in 1993 and since then, has become a leading venture investor in that sector. In 2005, the entire healthcare technology team of Sprout spun out into NLV.
Contact Phone:
+16468716400
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2017 | Deciphera Pharmaceuticals | Series C | 52M |
| 4/2015 | Edge Therapeutics | Series C | 56M |
| 5/2010 | Oxford Immunotec | Series D | 26M |
| 2/2011 | Versartis | Series B | 21M |
| 6/2013 | Bluesight | Series A | 10.4M |
| 5/2009 | Visiogen | Series D | 40M |
| 2/2012 | Truveris | Series B | 10M |
| 8/2019 | Qlaris Bio | Series A | 8.2M |
| 6/2021 | Cleerly | Series B | 0 |
| 8/2020 | ReViral | Series C | 0 |
| 2/2022 | Electra Therapeutics | Series B | 0 |
| 9/2019 | Edgewise Therapeutics | Series B | 50M |
| 10/2012 | ReShape Lifesciences | Post-IPO Equity | 15M |
| 3/2012 | GluMetrics | Venture Round | 13.3M |
| 11/2006 | Concert Pharmaceuticals | Series B | 48.5M |
| 10/2009 | Direct Flow Medical | Series C | 40M |
| 11/2012 | MEI Pharma | Post-IPO Equity | 27.5M |
| 8/2019 | Renovacor | Series A | 11M |
| 7/2008 | Interlace Medical | Series B | 7M |
| 4/2013 | Pearl Therapeutics | Venture Round | 41.7M |
| 9/2007 | Pearl Therapeutics | Series A | 15.5M |
| 11/2012 | Pearl Therapeutics | Series D | 65M |
| 10/2007 | Relypsa | Series A | 33M |
| 5/2016 | AVEO Oncology | Post-IPO Equity | 17M |
| 6/2011 | Aviir | Venture Round | 3M |
| 5/2018 | IRLAB Therapeutics | Series A | 15.8M |
| 5/2007 | Interlace Medical | Series B | 3M |
| 10/2020 | TigerConnect | Series D | 0 |
| 6/2015 | Advanced Cell Diagnostics | Series C | 22M |
| 11/2006 | Aesthetic Sciences | Series A | 6M |
| 7/2018 | Alector | Series E | 133M |
| 3/2016 | Iterum Therapeutics plc | Series A | 40M |
| 9/2013 | Catalyst Pharmaceuticals Partners | Post-IPO Equity | 15.1M |
| 11/2007 | Oriel Therapeutics | Venture Round | 26.5M |
| 8/2020 | Saniona | Post-IPO Equity | 0 |
| 6/2020 | BrightInsight | Series B | 40M |
| 10/2010 | Convergence Pharmaceuticals | Series A | 35.4M |
| 5/2016 | Aptinyx | Series A | 0 |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 2/2011 | Chimerix | Series F | 45M |
| 4/2018 | Rallybio | Series A | 37M |
| 12/2009 | Afferent Pharmaceuticals | Series A | 23M |
| 9/2019 | BrightInsight | Series A | 25M |
| 6/2016 | Kit Check | Series C | 0 |
| 10/2013 | Versartis | Series D | 0 |
| 8/2015 | ReShape Lifesciences | Post-IPO Equity | 38M |
| 4/2013 | iRhythm Technologies | Series D | 16M |
| 1/2012 | iRhythm Technologies | Private Equity Round | 12.2M |
| 5/2011 | iRhythm Technologies | Series C | 15M |
| 7/2010 | Artisan Pharma | Series C | 0 |
| 8/2021 | Dice Therapeutics | Series C | 60M |
| 6/2013 | Kit Check | Series A | 10.4M |
| 4/2020 | Rallybio | Series B | 0 |
| 6/2012 | Awarepoint | Venture Round | 14M |
| 10/2009 | Neuronetics | Series D | 0 |
| 10/2012 | Access Closure | Venture Round | 0 |
| 7/2015 | Afferent Pharmaceuticals | Series C | 55M |
| 3/2011 | Synageva BioPharma | Venture Round | 0 |
| 6/2007 | BioRelix | Series A | 25.8M |
| 10/2010 | WorldHeart | Venture Round | 25.3M |
| 1/2012 | Access Closure | Venture Round | 0 |
| 2/2007 | Visiogen | Venture Round | 24M |
| 9/2010 | Intarcia Therapeutics | Debt Financing | 5M |
| 3/2021 | BrightInsight | Series C | 101M |
| 2/2010 | Tioga Pharmaceuticals | Venture Round | 18M |
| 8/2009 | SchoolCare | Series G | 14.4M |
| 2/2009 | ReShape Medical | Series B | 20M |
| 1/2016 | AiCure | Series A | 12.3M |
| 10/2012 | Pearl Therapeutics | Private Equity Round | 23.3M |
| 7/2009 | Presidio Pharmaceuticals | Venture Round | 27M |
| 6/2012 | Oxford Immunotec | Equity | 28M |
| 6/2009 | VaxInnate | Series D | 30M |
| 9/2006 | Artisan Pharma | Series A | 39M |
| 4/2014 | Intarcia Therapeutics | Venture Round | 0 |
| 12/2017 | Aptinyx | Series B | 70M |
| 7/2013 | Karyopharm Therapeutics | Series B | 19M |
| 5/2018 | Neurana Pharmaceuticals | Series A | 0 |
| 10/2009 | Synageva BioPharma | Series F | 0 |
| 9/2010 | Relypsa | Series B | 70M |
| 7/2008 | Pearl Therapeutics | Series A | 18M |
| 10/2010 | Pearl Therapeutics | Series C | 69M |
| 1/2006 | Tioga Pharmaceuticals | Series A | 24M |
| 7/2012 | Vifor Pharma | Private Equity Round | 0 |
| 8/2015 | Principia Biopharma | Series B | 15.3M |
| 11/2021 | Asimily | Venture Round | 0 |
| 4/2013 | Treato | Series B | 14.5M |
| 10/2015 | Arvinas | Series B | 41.6M |
| 4/2014 | Principia Biopharma | Series B | 50M |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 8/2022 | Arine | Series B | 0 |
| 10/2012 | Relypsa | Venture Round | 2.6M |
| 8/2011 | Relypsa | Series B | 70.1M |
| 3/2012 | BioRelix | Venture Round | 2.6M |
| 9/2011 | CardioKinetix | Series E | 21M |
| 1/2018 | Braeburn | Debt Financing | 0 |
| 2/2010 | Pearl Therapeutics | Series C | 15M |
| 5/2014 | QPID Health | Series B | 12.3M |
| 9/2015 | Deciphera Pharmaceuticals | Series B | 75M |
| 9/2019 | Passage Bio | Series B | 110M |
| 2/2010 | Intrinsic Therapeutics | Venture Round | 18M |
| 6/2015 | Cogent Biosciences | Series B | 65M |
| 6/2016 | CRISPR Therapeutics | Series B | 0 |
| 10/2007 | Direct Flow Medical | Series B | 27M |
| 4/2015 | Dimension Therapeutics | Series B | 65M |
| 11/2012 | Advanced Cell Diagnostics | Series B | 12M |
| 3/2007 | Transcept Pharmaceuticals | Series D | 40M |
| 2/2011 | Spine Wave | Series E | 17.5M |
| 3/2010 | Access Closure | Venture Round | 10M |
| 11/2015 | ObsEva | Series B | 60M |
| 11/2012 | Intarcia Therapeutics | Debt Financing | 50M |
| 10/2018 | CuraSen Therapeutics | Series A | 54.5M |
| 8/2018 | ReViral | Series B | 0 |
| 11/2012 | Intarcia Therapeutics | Venture Round | 160M |
| 6/2010 | Altura Medical | Series A | 20M |
| 10/2009 | Aviir | Venture Round | 1M |
| 2/2011 | Spiracur | Series C | 35M |
| 4/2008 | IlluminOss Medical | Series B | 11M |
| 8/2012 | Vifor Pharma | Series C | 0 |
| 12/2008 | Aviir | Venture Round | 7.8M |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 12/2011 | Aviir | Venture Round | 10M |
| 8/2007 | ReShape Lifesciences | Series A | 3M |
| 6/2013 | Aviir | Series B | 10M |
| 1/2010 | Aviir | Venture Round | 4.2M |
| 9/2007 | Aviir | Series B | 11.3M |
| 1/2008 | Sopherion Therapeutics | Venture Round | 0 |
| 3/2010 | Aureon Laboratories | Series C | - |
| 3/2007 | ProteoGenix | Series B | 20M |
| 10/2012 | Principia Biopharma | Series A | 12.5M |
| 9/2012 | Karus Therapeutics | Series B | 7.6M |
| 12/2018 | Bellus Health | Post-IPO Equity | 26M |
| 9/2017 | Truveris | Series D | 25M |
| 3/2008 | Spiration | Series G | 18.5M |
| 4/2018 | Arvinas | Series C | 55M |
| 10/2006 | VaxInnate | Series C | 40M |
| 6/2016 | Bluesight | Series C | 20.4M |
| 1/2015 | Bluesight | Series B | 12M |
| 1/2014 | TigerConnect | Series B | 23M |
| 9/2012 | IlluminOss Medical | Series C | 0 |
| 3/2013 | CardioKinetix | Series E | 23M |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 7/2009 | Interlace Medical | Series C | 20.5M |
| 6/2017 | Neuronetics | Series G | 0 |
| 4/2015 | Neuronetics | Series F | 0 |
| 5/2017 | Harpoon Therapeutics | Series B | 45M |
| 5/2011 | Neuronetics | Series E | 30M |
| 3/2007 | Intarcia Therapeutics | Venture Round | 50M |
| 4/2010 | Aureon Laboratories | Series D | 7M |
| 4/2012 | Direct Flow Medical | Venture Round | 0 |
| 4/2008 | Concert Pharmaceuticals | Series C | 0 |
| 7/2013 | Versartis | Series C | 0 |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 4/2006 | Spiration | Series F | 13.4M |
| 8/2008 | GluMetrics | Series C | 20.1M |
| 4/2008 | Stromedix | Series B | 25M |
| 2/2009 | ReShape Lifesciences | Post-IPO Equity | 20M |
| 1/2013 | Versartis | Series C | 0 |
| 2/2013 | Aviir | Series B | 10M |
| 9/2015 | Kyruus | Series C | 25M |
| 11/2019 | AiCure | Series C | 24.5M |
| 8/2015 | Wave Life Sciences | Series B | 66M |
| 2/2022 | Star Therapeutics | Venture Round | 0 |
| 5/2021 | Akili Interactive Labs | Series D | 0 |
| 7/2020 | Glympse Bio | Series B | 46.7M |
| 8/2008 | ProteoGenix | Series B | 8M |
| 12/2014 | CardioKinetix | Series F | 0 |
| 2/2014 | Versartis | Series E | 55M |
| 8/2006 | Interlace Medical | Series A | 750k |
| 10/2012 | Presidio Pharmaceuticals | Venture Round | 8M |
| 4/2018 | Kyruus | Corporate Round | 0 |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 6/2009 | Spiracur | Series B | 20.3M |
| 11/2018 | Harpoon Therapeutics | Series C | 70M |
| 1/2013 | GluMetrics | Debt Financing | 5.6M |
| 11/2017 | AiCure | Series B | 15M |
| 3/2018 | Technology Will Save Us | Series A | 0 |
| 2/2022 | Star Therapeutics | Venture Round | 0 |
| 2/2022 | Electra Therapeutics | Series B | 0 |
| 11/2021 | Asimily | Venture Round | 0 |
| 8/2021 | Dice Therapeutics | Series C | 0 |
| 6/2021 | Cleerly | Series B | 0 |
| 5/2021 | Akili Interactive Labs | Series D | 0 |
| 3/2021 | BrightInsight | Series C | 0 |
| 1/2021 | Dice Therapeutics | Series C | 0 |
| 10/2020 | TigerConnect | Series D | 0 |
| 8/2020 | ReViral | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
